Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia
Status:
Unknown status
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The study is an investigation to assess the capacity of ascending doses of CX1739 to
antagonize the respiratory depressive effect of remifentanil. The study will also investigate
whether ascending doses of CX1739 reduce the analgesic effect of remifentanil or alter the
BIS measure of sedation and will evaluate the safety of CX1739 when used in conjunction with
remifentanil.